Page 199 - 80 guidelines for the treatment of malaria_opt

ANNEX 9. Treatment of Plasmodium vivax, P. ovale and P. malariae infections

61. Doberstyn EB et al. Treatment of vivax malaria with sulfadoxine-pyrimethamine and with
pyrimethamine alone. Transactions of the Royal Society of Tropical Medicine and Hygiene,
1979, 73:15–17.
62. De Pecoulas PE et al. Sequence variations in the Plasmodium vivax dihydrofolate reductase
thymidylate synthase gene and their relationship with pyrimethamine resistance. Molecular
and Biochemical Parasitology, 1998; 92:265–273.
63. Imwong M et al. Association of genetic mutations in Plasmodium vivax dhfr with resistance
to sulfadoxine-pyrimethamine geographical and clinical correlates. Antimicrobial Agents
and Chemotherapy, 2001, 45:3122–3127.
64. Maguire JD et al. Chloroquine or sulfadoxine-pyrimethamine for the treatment of
uncomplicated Plasmodium falciparum malaria during an epidemic in Central Java,
Indonesia. Annals of Tropical Medicine and Parasitology, 2002, 96:655–668.
65. Tjitra E et al. Efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-
sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium
vivax dhfr mutations. Antimicrobial Agents and Chemotherapy, 2002, 46:3947–3053.
66. Imwong M et al. Novel point mutations in the dihydrofolate reductase gene of Plasmodium
vivax: evidence for sequential selection by drug pressure. Antimicrobial Agents and
Chemotherapy, 2003, 47:1514–1521.
67. Hasting MD et al. Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia
and therapeutic response to sulfadoxine plus pyrimethamine. Journal of Infectious Diseases,
2004, 189:744–7450.
68. Kolaczinski K et al. Sulfadoxine-pyrimethamine plus artesunate compared with chloroquine
for the treatment of vivax malaria in areas co-endemic for Plasmodium falciparum and
P. vivax: a randomized non-inferiority trial in eastern Afghanistan. Transactions of the
Royal Society of Tropical Medicine and Hygiene, 2007, 101:1081–1087.
69. Krudsood S et al. Clinical efficacy of chloroquine versus artemether-lumefantrine for
Plasmodium vivax treatment in Thailand. Korean Journal of Parasitology, 2007, 45:111–
114.
70. Hasugian AR et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine:
superior efficacy and post treatment prophylaxis against multidrug-resistant Plasmodium
falciparum and Plasmodium vivax malaria. Clinical Infectious Diseases, 2007, 44:1067–
1074.
71. Ratcliff A et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum
and vivax malaria in Papua, Indonesia: an open-label randomized comparison. Lancet,
2007, 369:757–765.
72. The use of antimalarial drugs. Report of an informal consultation. Geneva, World Health
Organization, 2001. A9
73. Cooper RD, Rieckmann KH. Efficacy of amodiaquine against a chloroquine-resistant strain
of Plasmodium vivax. Transactions of the Royal Society of Tropical Medicine and Hygiene,
1990, 84:473.
74. Rieckmann KH. Monitoring the response of malaria infections to treatment. Bulletin of
the World Health Organization, 1990, 68:759–760.

185